The Industry’s Most Advanced Core Lab Delivering Next Generation Cardiac Safety Services

iCardiac Technologies, Inc, provides drug development companies worldwide with the complete range of core lab services. Its team of cardiac safety experts collectively bring over 100 years of cardiology, electrophysiology, drug development, regulatory and academic experience. The iCardiac team pioneered the field of autonomic nervous system effects on the QT interval, a phenomenon estimated to produce false-positive results in conventional QT studies for as many as 25% of all molecules currently in clinical development. iCardiac team members are active contributors on several FDA working groups that are advancing the field of cardiac safety.

iCardiac’s core laboratory services include scientific and regulatory consultation, protocol development, and end-to-end project and data management.

COMPAS: The Leading ICH E14 Compliant Solution to Reduce Cost and Eliminate False Positives/Negatives in Cardiac Safety Studies

COMPAS was originally developed at the University of Rochester Heart Research Follow-Up Program, the international leader in the study of congenital Long QT Syndrome and electrophysiology research, and it has been used in clinical QT studies for more than a decade.

The COMPAS platform provides comprehensive analysis of cardiac repolarization signals and contains several advanced ECG signal processing tools. Thorough QT Plus^sm improves the precision of ECG extraction and QT measurements and helps reduce the sample size of a TQT study. QTbtb^sm reduces the probability of false positive or negative results in QT studies by allowing for quantification of QT interval changes under varying conditions of heart rate and autonomic tone. Beyond QT^sm and Restitution provide exploratory analytical services aimed at determining the relative arrhythmia risk of a QT-prolonging compound.

Our team of scientists and board-certified cardiologists boast expertise in world-wide multi-center, clinical research studies ranging from 100-3,500 subjects. The team’s experience represents all major therapeutic areas.